Knight Therapeutics (TSE:GUD) Posts Quarterly Earnings Results

Knight Therapeutics (TSE:GUD) posted its quarterly earnings data on Thursday. The company reported C($0.03) EPS for the quarter, FiscalAI reports. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%.The business had revenue of C$143.97 million during the quarter.

Here are the key takeaways from Knight Therapeutics’ conference call:

• Record first-half performance: Knight reported CAD 293 million in revenue, CAD 52 million in adjusted EBITDA, and CAD 70 million in operating cash flow, supported by 36% constant-currency growth in its promoted portfolio.
• 2026 guidance was raised to CAD 540–560 million in revenue, representing at least 20% growth, with adjusted EBITDA expected to reach at least 15% of revenue. Management attributed the increase primarily to stronger promoted-product performance, with only a limited ongoing benefit from foreign exchange.
• Knight’s launch pipeline generated CAD 18 million in second-quarter revenue, up 297% year over year on a constant-currency basis, while adjusted EBITDA rose 58% to more than CAD 24 million. Management expects margins to improve over the next several years as recent launches scale and infrastructure spending stabilizes.
• Health Canada issued a Notice of Non-Compliance for CREXONT, creating uncertainty around its Canadian launch timeline while Knight works with its partner on a response. In addition, LENVIMA is expected to face a material price reduction in Colombia, and AmBisome sales to Brazil’s Ministry of Health are not expected to recur in the second half.

Knight Therapeutics Stock Up 2.6%

Shares of TSE:GUD traded up C$0.24 during trading on Thursday, hitting C$9.50. 222,367 shares of the company’s stock traded hands, compared to its average volume of 97,979. Knight Therapeutics has a 52 week low of C$5.66 and a 52 week high of C$10.17. The company has a 50-day moving average price of C$9.44 and a 200-day moving average price of C$7.81. The company has a market cap of C$932.70 million, a price-to-earnings ratio of 158.33, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.19. The company has a current ratio of 2.32, a quick ratio of 1.79 and a debt-to-equity ratio of 8.86.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group set a C$9.50 price target on shares of Knight Therapeutics and gave the company a “buy” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of C$9.50.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.